Rest/Stress Quantification Of Left Ventricular Dyssynchrony By 3D Gated Blood Pool D-SPECT

Left Ventricular Dyssynchrony: Rest/Stress 3D Blood-Pool Gated D-SPECT Quantification With a High-Speed Dedicated Cardiac Camera Before CRT

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01390532

Enrollment

Registered

2011-07-11

Start date

2010-08-31

Completion date

2011-10-31

Last updated

2011-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Dyssynchrony

Keywords

Left Ventricular Dyssynchrony, Gated blood-pool, D-SPECT, Pharmacological stress, NYHA III/IV, LVEF < 35 %, QRS > 120 ms, optimal medical treatment, cardiac resynchronization therapy

Brief summary

Cardiac Resynchronization Therapy (CRT) is an established treatment for patients with advanced heart failure and left ventricular dyssynchrony (LVD). Too many patients do not clinically improve with CRT. New LVD markers other than QRS duration are needed. Study objective : feasibility assessment of rest and real-time stress 3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel) to quantify LVD.

Detailed description

Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR). Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA).

Interventions

DEVICE3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Chronic heart failure with LVEF \< 35 %, QRS \> 120 ms, NYHA III/IV, optimal medical therapy for more than one month. * Patient with stable hemodynamic for more than one month, * More than 18-year old man or woman, * Patient having given his free, inform and signed consent, * Patient place setting by the social security system,

Exclusion criteria

* Psychiatric disorder * Any contra-indication to Technetium, * Any contra-indication to dobutamin or atropin * Personal or family history of sudden death * Previous severe ventricular arrhythmia * Obstructive cardiomyopathy, severe aortic stenosis, * Pulmonary hypertension, * History of renal, lung, hepatic, cardiac transplantation, * Pregnant or breast-feeding Woman, * Patient who can not conform to the requirements of the protocol, * Patient included in another medical study,

Design outcomes

Primary

Measure	Time frame
Left ventricular phase standard deviation.	—

Secondary

Measure	Time frame
Left ventricular entropy	—
Left ventricle ejection fraction	—
Quality of life.	—
6-minutes walking test	—

Countries

France

Contacts

Primary ContactPatrick LACARIN

placarin@chu-clermontferrand.fr04 73 75 11 95

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026